Search Result
Results for "
Collagen-induced arthritis
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-153808
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
|
-
-
- HY-153808A
-
|
|
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Incomplete Freund's adjuvant (IFA) (Montanide ISA-51) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund. Incomplete Freund's adjuvant (IFA) does not contain inactivated tuberculosis bacilli and consists of petroleum jelly containing lanolin. Incomplete Freund's adjuvant (IFA) induces high antibody titers and long-lasting effector T cell responses with no long-term effects on collagen disease, tumors, or death. Complete Freund's adjuvant (CFA) (HY-153808) is another type of Freund's Adjuvant that stimulates a stronger immune response .
|
-
-
- HY-153321
-
|
NX-5948; BTK-IN-24
|
PROTACs
Btk
|
Inflammation/Immunology
Cancer
|
|
Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
|
-
-
- HY-168625
-
|
|
Molecular Glues
|
Inflammation/Immunology
|
|
VAV1 degrader-3 (Example 185) is an orally active VAV1 molecular glue degrader (DC50: 7 nM). VAV1 degrader-3 reduces immune cell activation, immune cell proliferation and the production of various cytokines. VAV1 degrader-3 can be used for research of inflammatory or autoimmune disorder. VAV1 degrader-3 inhibits disease progression in experimntal autoimmune encephalomyelitis (EAE) mouse model, Collagen-induced arthritis (CIA) mouse model, etc. .
|
-
-
- HY-123606
-
GSK484
Maximum Cited Publications
49 Publications Verification
|
Protein Arginine Deiminase
MHC
|
Cardiovascular Disease
Inflammation/Immunology
|
|
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .
|
-
-
- HY-P990151
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonal antibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA) .
|
-
-
- HY-108559
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice .
|
-
-
- HY-110177
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA) .
|
-
-
- HY-114495
-
|
Cerulomycin; Caerulomycin
|
Fungal
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma .
|
-
-
- HY-101448
-
TMI-1
1 Publications Verification
WAY-171318
|
MMP
Apoptosis
Interleukin Related
TNF Receptor
Caspase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
|
-
-
- HY-164894
-
-
-
- HY-139780
-
|
|
ROR
|
Inflammation/Immunology
|
|
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .
|
-
-
- HY-P10086
-
|
Human TREM-1(213-221)
|
TREM receptor
TNF Receptor
Interleukin Related
c-Fms
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer .
|
-
-
- HY-N0899
-
|
|
JAK
STAT
Wnt
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Wilforine is an orally active JAK-STAT pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome .
|
-
-
- HY-P99529
-
|
BAX1810; TAK-752; SM101
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .
|
-
-
- HY-P5003
-
|
|
MMP
|
Inflammation/Immunology
|
|
Collagen Type II Fragment is an anti-inflammatory peptide that potently inhibits collagen-induced arthritis (CIA) in mice. Collagen Type II Fragment can be used for research on inflammation and immunity .
|
-
-
- HY-136990
-
|
|
p38 MAPK
|
Cancer
|
|
GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .
|
-
-
- HY-123133
-
|
|
Kallikrein
|
Inflammation/Immunology
|
|
PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system .
|
-
-
- HY-177435
-
|
|
FAP
|
Inflammation/Immunology
|
|
FAPI-800CW is a near-infrared (NIR) fluorescent-labeled fibroblast activation protein (FAP) inhibitor. FAPI-800CW shows specific uptake in inflamed paws in collagen-induced arthritis (CIA) model mice. FAPI-800CW can be used for in vivo molecular imaging of FAP expression in inflammatory diseases such as rheumatoid arthritis (RA) to monitor joint inflammation and disease activity .
|
-
-
- HY-N9794
-
|
|
Others
|
Inflammation/Immunology
|
|
Isoboldine is a pyridine alkaloid. Isoboldine effectively alleviates inflammation and joint destruction in collagen-induced arthritis in mice .
|
-
-
- HY-122906
-
|
|
c-Fms
|
Inflammation/Immunology
|
|
JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .
|
-
-
- HY-18164
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
TASP0277308 is a highly selective S1P1 antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice .
|
-
-
- HY-167692
-
|
|
STAT
|
Others
|
|
JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.
|
-
-
- HY-178012
-
|
|
IRAK
TNF Receptor
|
Inflammation/Immunology
|
|
GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC50 of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .
|
-
-
- HY-151093
-
-
-
- HY-138007
-
|
|
ROR
PPAR
LXR
|
Metabolic Disease
Inflammation/Immunology
|
|
SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
|
-
-
- HY-W004681
-
|
6-Methyl-3-pyridinol
|
Drug Intermediate
|
Inflammation/Immunology
|
|
6-Methyl-3-pyridinol (5-hydroxy-2-methylpyridine) is a starting compound for the synthesis of L-azatyrosine (HY-W048303). 6-Methyl-3-pyridinol can be isolated from cigarette smoke condensate. 6-Methyl-3-pyridinol aggravates Collagen-induced arthritis in mice .
|
-
-
- HY-120041
-
|
|
IRAK
|
Cancer
|
|
ND-2158 is a competitive IRAK4 inhibitor, with the Ki of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo .
|
-
-
- HY-117622
-
|
|
IRAK
|
Inflammation/Immunology
Cancer
|
|
ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets
the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
|
-
-
- HY-120050
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels .
|
-
-
- HY-155031
-
|
|
Reactive Oxygen Species (ROS)
COX
|
Inflammation/Immunology
Cancer
|
|
MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC50 value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA) .
|
-
-
- HY-153321A
-
|
(R,R)-NX-5948; (R,R)-BTK-IN-24
|
Drug Isomer
PROTACs
Btk
|
Inflammation/Immunology
Cancer
|
|
(R,R)-Bexobrutideg is the (R,R)-enantiomer of Bexobrutideg (HY-153321). Bexobrutideg (NX-5948) is an orally active PROTAC that induces specific BTK protein degradation via a cereblon E3 ligase (CRBN) complex without degrading other cereblon neo substrates. Bexobrutideg mediates potent anti-inflammatory activity through BTK degradation, thereby inhibiting B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models containing wild-type BTK or BTKi resistance mutations. Bexobrutideg is effective in a mouse model of collagen-induced arthritis (CIA). Bexobrutideg can cross the blood-brain barrier. NX-5948 consists of a target protein ligand, a linker, and a VHL E3 ubiquitin ligase (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
|
-
-
- HY-163673
-
|
|
Glucocorticoid Receptor
Drug-Linker Conjugates for ADC
|
Inflammation/Immunology
|
|
Glucocorticoid receptor modulator 4 (Compound DL5) is a conjugate of a linker and a glucocorticoid receptor modulator. Glucocorticoid receptor modulator 4 exhibits GRE Reporter activity in mTNF expressing K562 cell with an EC50 of 40 μM. Glucocorticoid receptor modulator 4 binds with an anti-tumor necrosis factor (TNF) antibody, and exhibits anti-inflammtory activity against arthritis in mouse models .
|
-
-
- HY-147660
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research .
|
-
-
- HY-119298
-
|
|
p38 MAPK
|
Inflammation/Immunology
|
|
AW-814141 is a selective and orally active p38 MAP kinase inhibitor. AW-814141 has an IC50 values of 100 nM and 158 nM for p38-α and β isoforms, respectively. AW-814141 can inhibit the production of TNF-α induced by LPS (HY-D1056). AW-814141 can inhibit paw edema in rats in a dose-dependent manner. AW-814141 exhibits anti-inflammatory activity and can be used in the research of inflammatory diseases such as rheumatoid arthritis .
|
-
-
- HY-N14973
-
|
|
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Epoxyquinomicin D is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin D exhibits anti-inflammatory effects against collagen-induced arthritis .
|
-
-
- HY-N14977
-
|
|
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Epoxyquinomicin C is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin C exhibits anti-inflammatory effects against collagen-induced arthritis. Epoxyquinomicin C can be designed for synthesis of the NF-κB Inhibitor DHMEQ .
|
-
-
- HY-P4684
-
|
PTHrP (107–111)
|
PTHR
|
Inflammation/Immunology
|
|
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
|
-
-
- HY-173518
-
|
|
Heme Oxygenase (HO)
Reactive Oxygen Species (ROS)
NO Synthase
COX
Interleukin Related
|
Inflammation/Immunology
|
|
SIN 14, a derivative of Sinomenine (HY-15122), is an orally active HO-1 activator (KD = 17.2 μM). SIN 14 binds to the catalytic core domain of HO-1 and induces HO-1 activation in catalysis. SIN 14 significantly increases HO-1 stability. SIN 14 has anti-inflammatory effects and inhibits M1 macrophage polarization while promoting M2 polarization in LPS (Lipopolysaccharides)(HY-D1056)-induced RAW264.7 cells. SIN 14 inhibits inflammatory mediator production (eg: NO, IL-6, IL-1β and CCL2, inhibits production of ROS and down-regulates the expression of COX-2 and iNOS. SIN 14 can inhibit RA-related inflammatory edema in collagen-induced arthritis (ClA) mice .
|
-
-
- HY-N12141
-
|
|
Apoptosis
|
Inflammation/Immunology
|
|
Flaccidoside II inhibits proliferation and induces apoptosis in Malignant peripheral nerve sheath tumors (MPNSTs) cell lines. Flaccidoside II ameliorates collagen-induced arthritis in mice. Flaccidoside II is an active triterpenoid saponin constituent from Anemone flaccida rhizome .
|
-
-
- HY-179216
-
|
|
HDAC
|
Neurological Disease
Inflammation/Immunology
|
|
KTT-1 is a kinetically selective and orally active HDAC2 inhibitor. KTT-1 exhibits high HDAC2-selectivity over HDAC1. KTT-1 inhibits osteoclast differentiation at an early stage by downregulating c-Fos expression. KTT-1 effectively suppresses arthritis symptoms in the collagen-induced arthritis (CIA) mouse model. KTT-1 can be used for the research of rheumatoid arthritis and neurodegenerative diseases .
|
-
-
- HY-163651
-
|
(R)-CR6086
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
(R)-Vorbipiprant ((R)-CR6086) is an orally active antagonist for prostaglandin E2 receptor 4 (EP4) with Ki of 16.6 nM for human EP4. (R)-Vorbipiprant inhibits PGE2 (HY-101952)-induced cAMP production with an IC50 of 22 nM. (R)-Vorbipiprant exhibits immunomodulatory and anti-angiogenic activities, and ameliorates the collagen-induced arthritis in mice .
|
-
-
- HY-N14238
-
|
|
Antibiotic
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Epoxyquinomicin B is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin B exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 6.25-12.5 µg/mL. Epoxyquinomicin B exhibits cytotoxicity in cancer cell L1210 with IC50 of 16.3 µg/mL. Epoxyquinomicin B exhibits anti-inflammatory effects against collagen-induced arthritis .
|
-
-
- HY-108559R
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
L-161982 (Standard) is the analytical standard of L-161982. This product is intended for research and analytical applications. L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice .
|
-
-
- HY-N14237
-
|
|
Antibiotic
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Epoxyquinomicin A is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin A exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 3-12.5 µg/mL. Epoxyquinomicin A exhibits cytotoxicity in cancer cell L1210, B16 and S180 with IC50 of 2-8 µg/mL. Epoxyquinomicin A exhibits anti-inflammatory effects against collagen-induced arthritis .
|
-
-
- HY-117767
-
|
|
mTOR
|
Inflammation/Immunology
|
|
CZ830 is a mTOR kinase inhibitor with an IC50 of < 1 μM. CZ830 is applicable to the research of collagen-induced arthritis .
|
-
-
- HY-111749
-
-
-
- HY-N16371
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid (Compound MC-1), an isocoumarin, is a metabolite of Cytogenin (HY-19606). 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid has anti-angiogenic activity in S-180 implanted dorsal air sac mice model. 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid also modifies collagen-induced arthritis. 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid can be used for cancers and inflammatory diseases research .
|
-
-
- HY-N16465
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
STAT
|
Inflammation/Immunology
|
|
Cinnamtannin D1 is an orally active polyphenolic compound with immunosuppressive activity. Cinnamtannin D1 regulates the balance of Th17/Treg cells by inhibiting AHR expression. Cinnamtannin D1 reduces apoptosis and ROS in INS-1 cells and primary cultured murine islets induced by Palmitic acid (PA) (HY-N0830). Cinnamtannin D1 reduces Th17 cell differentiation via downregulating p-STAT3/RORγt and promotes Treg cell differentiation via upregulating p-STAT5/Foxp3. Cinnamtannin D1 exerts excellent anti-arthritic efficacy in collagen-induced arthritis (CIA) model of mice. Cinnamtannin D1 can be used for the study of rheumatoid arthritis (RA) .
|
-
-
- HY-P992000
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
F8-IL-4 is an immune cytokine targeting IL-4. F8-IL-4 specifically delivers IL-4 to inflammatory sites via binding to targets expressed on neovascular vessels. F8-IL-4 alleviates collagen-induced arthritis in mice by regulating T cell subsets and macrophage polarization. When combined with Dexamethasone (HY-14648), F8-IL-4 produces a synergistic and long-lasting therapeutic effect, and prevents arthritis recurrence after drug withdrawal by maintaining anti-inflammatory cell phenotypes and cytokine profiles. F8-IL-4 can be used in the research of collagen-induced arthritis .
|
-
- HY-P10850
-
|
|
TNF Receptor
NF-κB
Apoptosis
|
Inflammation/Immunology
|
|
PIYLGGVFQ is a peptide inhibitor for TNF-α. PIYLGGVFQ inhibits TNF-α-mediated apoptosis, NF-κB nuclear translocation and activation. PIYLGGVFQ exhibits anti-arthritic activity in the CIA mouse model .
|
-
- HY-177277
-
|
|
PI3K
|
Inflammation/Immunology
|
|
HM5023507 is an orally active and selective PI3Kδ/γ inhibitor with IC50s of 4 and 5 μM for PI3Kδ and PI3Kγ over PI3Kβ and PI3Kα. HM5023507 attenuates the PI3Kδ/γ signaling in human basophils. HM5023507 also attenuates the activation and function of human B and T cells and cytokine and IgG production during cocultures, and Th17 differentiation of CD4 T cells. HM5023507 inhibited semiestablished collagen-induced arthritic inflammation in the rat models. HM5023507 can be used for inflammatory diseases like rheumatoid arthritis research .
|
-
- HY-112863
-
|
|
ROR
|
Inflammation/Immunology
|
|
RORγt inhibitor 3 is an orally active and potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor. RORγt inhibitor 3 shows high binding affinity and inhibitory activity of Th17 cell differentiation. RORγt inhibitor 3 also shows efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models .
|
-
- HY-181929
-
|
H018
|
JAK
|
Inflammation/Immunology
|
RAI-20 (H018) is an orally active JAK1/JAK2 dual inhibitor (IC50=15.1 and 22.7 nM). RAI-20 exhibits excellent pharmacokinetic properties, including plasma stability, systemic exposure, and a long half-life. In a collagen-induced arthritis rat model, RAI-20 shows significant anti-inflammatory and anti-arthritic activities, effectively reducing paw swelling volume and arthritis index. RAI-20 can be used for research on the pathogenesis of rheumatoid arthritis .
|
-
- HY-182884
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
TNF-α-IN-29 is an orally active and selective TNF-α inhibitor, with IC50 values of 123.0 nM against human targets, and a human Kd of 45.9 nM. TNF-α-IN-29 blocks TNF-α-TNFR1 protein-protein interactions and inhibits TNF-α-mediated inflammatory signaling pathways. TNF-α-IN-29 exhibits anti-inflammatory effects in a mouse model of collagen-induced arthritis and promotes articular cartilage repair. TNF-α-IN-29 can be used for the research of rheumatoid arthritis .
|
-
- HY-171296
-
|
|
p38 MAPK
JNK
|
Inflammation/Immunology
|
|
p38 Kinase inhibitor 8 (Compound CCLXXVIII) is the orally active inhibitor for p38β and JNK2α2 with IC50s of 6.3 nM and 53.6 nM. p38 Kinase inhibitor 8 exhibits anti-inflammatory effect in rats collagen-induced arthritis models .
|
-
- HY-14371
-
|
|
Drug Derivative
LPL Receptor
|
Inflammation/Immunology
|
|
LX2932 is an orally active LX2931 (HY-14370) analogue and S1P/S1PR signaling axis modulator. LX2932 yields a dose-dependent decrease in circulating lymphocyte numbers. LX2932 improves collagen-induced arthritis .
|
-
- HY-101448R
-
|
WAY-171318 (Standard)
|
MMP
Reference Standards
Apoptosis
Interleukin Related
TNF Receptor
Caspase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
TMI-1 (Standard) is the analytical standard of TMI-1 (HY-101448). This product is intended for research and analytical applications. TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
|
-
- HY-W782935
-
|
|
MAPKAPK2 (MK2)
|
Inflammation/Immunology
|
|
MAPKAPK5-IN-1 is a substitutedtriazolopyrazine or imidazopyrazine compound and MAPKAPK5 inhibitor.MAPKAPK5-IN-1 can be used for the research of rheumatoid arthritis .
|
-
- HY-165564
-
|
|
Drug Derivative
|
Inflammation/Immunology
|
|
SM-8849 is a thiazole derivative with anti-arthritis activity. SM-8849 specifically targets and inactivates T cells involved in delayed-type hypersensitivity (DTH) reactions, thereby inhibiting the core immunopathological process of arthritis, but has little effect on the humoral immune process such as antibody production. In a mouse arthritis model induced by Type II Collagen (HY-NP003), SM-8849 significantly alleviated clinical symptoms, reduced bone destruction and joint damage. SM-8849 can be used for the study of autoimmune diseases such as rheumatoid arthritis .
|
-
- HY-P11617
-
|
|
NF-κB
ERK
JNK
p38 MAPK
Interleukin Related
|
Inflammation/Immunology
|
|
CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis .
|
-
- HY-P992071
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Anti-Mouse NKG2D Antibody (MI6) is an antibody targeting mouse NKG2D. Anti-Mouse NKG2D Antibody (MI6) can be used in arthritis-related research. For the isotype control of Anti-Mouse NKG2D Antibody (MI6), please refer to Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
- HY-182579
-
|
|
p38 MAPK
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
CBS-3408 is an orally active p38α MAPK inhibitor. CBS-3408 inhibits the release of TNFα and IL-1β. CBS-3408 reduces the disease severity of arthritis in mice. CBS-3408 inhibits TNFα release in a rat endotoxemia model. CBS-3408 can be used in studies related to endotoxemia and arthritis .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-164894
-
|
|
Fluorescent Dyes
|
ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC). ABBV-3373 consists of a humanized TNF antibody Adalimumab (HY-P9908) conjugated to a glucocorticoid receptor agonist (HY-148436). ABBV-3373 can be used for the research of rheumatoid arthritis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10086
-
|
Human TREM-1(213-221)
|
TREM receptor
TNF Receptor
Interleukin Related
c-Fms
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer .
|
-
- HY-P5003
-
|
|
MMP
|
Inflammation/Immunology
|
|
Collagen Type II Fragment is an anti-inflammatory peptide that potently inhibits collagen-induced arthritis (CIA) in mice. Collagen Type II Fragment can be used for research on inflammation and immunity .
|
-
- HY-P4684
-
|
PTHrP (107–111)
|
PTHR
|
Inflammation/Immunology
|
|
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
|
-
- HY-P10850
-
|
|
TNF Receptor
NF-κB
Apoptosis
|
Inflammation/Immunology
|
|
PIYLGGVFQ is a peptide inhibitor for TNF-α. PIYLGGVFQ inhibits TNF-α-mediated apoptosis, NF-κB nuclear translocation and activation. PIYLGGVFQ exhibits anti-arthritic activity in the CIA mouse model .
|
-
- HY-P11617
-
|
|
NF-κB
ERK
JNK
p38 MAPK
Interleukin Related
|
Inflammation/Immunology
|
|
CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P990151
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonal antibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA) .
|
-
(5)
-
- HY-P99529
-
|
BAX1810; TAK-752; SM101
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .
|
-
(5)
-
- HY-P992000
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
F8-IL-4 is an immune cytokine targeting IL-4. F8-IL-4 specifically delivers IL-4 to inflammatory sites via binding to targets expressed on neovascular vessels. F8-IL-4 alleviates collagen-induced arthritis in mice by regulating T cell subsets and macrophage polarization. When combined with Dexamethasone (HY-14648), F8-IL-4 produces a synergistic and long-lasting therapeutic effect, and prevents arthritis recurrence after drug withdrawal by maintaining anti-inflammatory cell phenotypes and cytokine profiles. F8-IL-4 can be used in the research of collagen-induced arthritis .
|
-
(5)
-
- HY-P992071
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Anti-Mouse NKG2D Antibody (MI6) is an antibody targeting mouse NKG2D. Anti-Mouse NKG2D Antibody (MI6) can be used in arthritis-related research. For the isotype control of Anti-Mouse NKG2D Antibody (MI6), please refer to Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-114495
-
-
-
- HY-N0899
-
-
-
- HY-N9794
-
-
-
- HY-N14973
-
-
-
- HY-N14977
-
|
|
Natural Products
Microorganisms
Source Classification
|
Antibiotic
|
|
Epoxyquinomicin C is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin C exhibits anti-inflammatory effects against collagen-induced arthritis. Epoxyquinomicin C can be designed for synthesis of the NF-κB Inhibitor DHMEQ .
|
-
-
- HY-N12141
-
-
-
- HY-N14238
-
|
|
Microorganisms
Antibiotics
Other Antibiotics
Source Classification
|
Antibiotic
Bacterial
|
|
Epoxyquinomicin B is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin B exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 6.25-12.5 µg/mL. Epoxyquinomicin B exhibits cytotoxicity in cancer cell L1210 with IC50 of 16.3 µg/mL. Epoxyquinomicin B exhibits anti-inflammatory effects against collagen-induced arthritis .
|
-
-
- HY-N14237
-
|
|
Microorganisms
Antibiotics
Other Antibiotics
Source Classification
|
Antibiotic
Bacterial
|
|
Epoxyquinomicin A is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin A exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 3-12.5 µg/mL. Epoxyquinomicin A exhibits cytotoxicity in cancer cell L1210, B16 and S180 with IC50 of 2-8 µg/mL. Epoxyquinomicin A exhibits anti-inflammatory effects against collagen-induced arthritis .
|
-
-
- HY-N16371
-
|
|
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
Endogenous Metabolite
|
|
6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid (Compound MC-1), an isocoumarin, is a metabolite of Cytogenin (HY-19606). 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid has anti-angiogenic activity in S-180 implanted dorsal air sac mice model. 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid also modifies collagen-induced arthritis. 6-Methoxy-8-hydroxyisocoumarin-3-carboxylic acid can be used for cancers and inflammatory diseases research .
|
-
-
- HY-N16465
-
|
|
Phenols
Polyphenols
Plants
Lauraceae
Lindera glauca (Siebold & Zucc.) Blume
Source Classification
|
Apoptosis
Reactive Oxygen Species (ROS)
STAT
|
|
Cinnamtannin D1 is an orally active polyphenolic compound with immunosuppressive activity. Cinnamtannin D1 regulates the balance of Th17/Treg cells by inhibiting AHR expression. Cinnamtannin D1 reduces apoptosis and ROS in INS-1 cells and primary cultured murine islets induced by Palmitic acid (PA) (HY-N0830). Cinnamtannin D1 reduces Th17 cell differentiation via downregulating p-STAT3/RORγt and promotes Treg cell differentiation via upregulating p-STAT5/Foxp3. Cinnamtannin D1 exerts excellent anti-arthritic efficacy in collagen-induced arthritis (CIA) model of mice. Cinnamtannin D1 can be used for the study of rheumatoid arthritis (RA) .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-153808
-
|
|
|
Adjuvant
|
|
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
|
-
- HY-153808A
-
|
|
|
Adjuvant
|
|
Incomplete Freund's adjuvant (IFA) (Montanide ISA-51) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund. Incomplete Freund's adjuvant (IFA) does not contain inactivated tuberculosis bacilli and consists of petroleum jelly containing lanolin. Incomplete Freund's adjuvant (IFA) induces high antibody titers and long-lasting effector T cell responses with no long-term effects on collagen disease, tumors, or death. Complete Freund's adjuvant (CFA) (HY-153808) is another type of Freund's Adjuvant that stimulates a stronger immune response .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: